Results 151 to 160 of about 53,966 (229)

RNA‐Binding Proteins and Ferroptosis in Cancer: Mechanism and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ferroptosis critically influences cancer cell fate and represents a promising therapeutic strategy. Emerging evidence identifies RNA‐binding proteins (RBPs) as key post‐transcriptional regulators of ferroptosis. The figure summarizes ferroptosis‐related RBPs across cancers: blue RBPs act as tumor suppressors by promoting ferroptosis, whereas red RBPs ...
Linlin Chang, Bin Lu, Haotian Shang, Wanjing Ding, Chunhua Wei, Xiaotian Qi, Pengxing He   +6 more
wiley   +1 more source

Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma. [PDF]

Int J Biol Sci
Jang HR, Kim HJ, Kim BY, Jeong JH, Kim JK, Won JA, Yoo HH, Lee YG, Yim H.   +8 more
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced <i>KRAS</i>-Mutated Metastatic Pancreatic Cancer. [PDF]

J Immunother Precis Oncol
Khawaja MR, Jameson G, Cridebring D, Shannon P, Han H, Moore J, Von Hoff D, Posner RG, Hlavacek WS, Kolch W, Kholodenko BN, Rukhlenko OS, Roe DJ, Wertheim BC, Borazanci E.   +14 more
europepmc   +1 more source

Correction to “circRNA‐SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis”

MedComm, Volume 7, Issue 4, April 2026.
wiley   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

SIRT7 Orchestrates Ligand‐Dependent ERα Signaling Rewiring to Drive Tamoxifen Resistance in ERα‐positive Breast Cancer

MedComm – Oncology, Volume 5, Issue 1, March 2026.
In tamoxifen‐sensitive breast cancer, SIRT7 deacetylates ERα at lysines 302 and 303, promoting CHIP‐mediated, ubiquitin‐dependent proteasomal degradation of ERα and thereby restraining estrogen‐driven tumor growth. By contrast, during tamoxifen treatment, enhanced interaction between SIRT7 and ERα redirects deacetylated ERα toward activation of EGFR ...
Yalan Wu, Huixia Liu, Ye Liu, Yanxue Mei, Mengdi Cao, Guo Li, Ronghui Fan, Junfeng Zhang, Langmei Yang, Jieling Liu, Qi Hou, Jinsong Li, Fujun Dai, Baohua Liu, Xiaolong Tang   +14 more
wiley   +1 more source

Commentary: Novel mtDNA methylation-associated prognostic signatures in colorectal cancer. [PDF]

Front Oncol
Jiang X, Zhang X, Wang M.
europepmc   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

SLC25A39 facilitates Sorafenib resistance in hepatocellular carcinoma by inhibiting mitochondrial oxidative stress-induced ferroptosis. [PDF]

Cancer Cell Int
Geng X, Li J, Wu B, Wang W, Li Z, Liu S, Li H, Chang H.   +7 more
europepmc   +1 more source